(LINC) L - Ratings and Ratios

Linc AB is a Nordic private equity and venture capital firm specializing in investments across the pharmaceutical, life-science, and med-tech sectors. The firm adopts a dual-strategy approach, targeting early-stage drug development projects for their high growth potential and mature medical technology companies for their stability and market validation. Its investment portfolio spans both private and public entities, including research-focused and operational businesses. Linc AB demonstrates a strong preference for Nordic-based companies, leveraging its regional expertise to identify and nurture promising ventures. The firm typically initiates investments with amounts ranging from SEK 25 million to SEK 250 million ($2.99 million to $29.99 million), often starting with smaller allocations and scaling up with follow-on investments. Founded in 1991 and headquartered in Stockholm, Sweden, Linc AB has established itself as a key player in the Nordic investment landscape, with a focus on innovation and long-term value creation.

As of the latest data, Linc AB (ST:LINC) trades at 72.00 SEK, with a 20-day average volume of 77,608 shares. The stocks short-term momentum is reflected in its SMA-20 of 74.69, while its SMA-50 and SMA-200 stand at 80.43 and 84.46, respectively, indicating a recent downtrend. The ATR of 2.60 suggests moderate volatility. From a fundamental perspective, the company boasts a market capitalization of 4,233.25M SEK, with a P/E ratio of 3.25, highlighting its undervaluation relative to earnings. The P/B ratio of 0.88 signals that the stock is trading below its book value, while the P/S ratio of 3.28 reflects its revenue multiple. Linc ABs return on equity (RoE) of 26.94% underscores its operational efficiency and profitability.